Study on Rozanolixizumab in Different Ethnic Groups
Author Information
Author(s): Assem el Baghdady, Rocío Lledó‐García, Maryam Gayfieva, Romana Lowcock, Shikiko Watanabe, Jagdev Sidhu, Denisa Wilkes
Primary Institution: UCB Slough UK
Hypothesis
How does the safety, tolerability, pharmacokinetics, and pharmacodynamics of rozanolixizumab compare among healthy Japanese, Chinese, and White participants?
Conclusion
Rozanolixizumab was found to be safe and well-tolerated across Japanese, Chinese, and White participants, with comparable pharmacokinetics and pharmacodynamics.
Supporting Evidence
- All treatment-emergent adverse events were mild to moderate in severity.
- No severe or serious adverse events occurred during the study.
- IgG levels decreased in a dose-dependent manner across all ethnicities.
Takeaway
This study tested a new medicine on people from different backgrounds to see if it works the same for everyone, and it did!
Methodology
This was a double-blind, single-center, Phase 1 study that randomized 65 participants to receive varying doses of rozanolixizumab.
Limitations
The study had relatively small subgroup sizes and was limited to a single dose of rozanolixizumab.
Participant Demographics
Participants included 22 Japanese, 20 Chinese, and 23 White individuals, with a median age of 29, 35, and 42 years respectively.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website